Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Labianca

Showing results (91-100 of 174) with videos related to

Pageof 18
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 28, 2008
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from ItalyMarcello Tiseo, Cesare Gridelli, Stefano Cascinu, et al.
Cancer Immunology, Immunotherapy : CII|September 26, 2009
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancerRodolfo Passalacqua, Carlo Buzio, Sebastiano Buti, et al.
Oncology|February 5, 2003
Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?Tommaso de Pas, Paolo G Casali, Salvatore Toma, et al.
Tumori|August 19, 2004
45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003Raffaella Giavazzi, Massimo Aglietta, Annalisa Astolfi, et al.
Clinical Colorectal Cancer|April 12, 2015
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II StudyNicola Personeni, Lorenza Rimassa, Claudio Verusio, et al.
The Lancet. Oncology|September 4, 2009
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind studyGiancarlo Agnelli, Gualberto Gussoni, Carlo Bianchini, et al.
European Urology|September 12, 2012
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY)Sergio Bracarda, Camillo Porta, Corrado Boni, et al.
The Lancet. Oncology|December 14, 2007
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trialStefano Cascinu, Rossana Berardi, Roberto Labianca, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 9, 2003
Pain and its treatment in hospitalized patients with metastatic cancerStefano Cascinu, Paolo Giordani, Romina Agostinelli, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 22, 2014
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinomaValentina Vaira, Massimo Roncalli, Carlo Carnaghi, et al.
Pageof 18

Showing results (91-100 of 174) with videos related to

Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|October 28, 2008
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from ItalyMarcello Tiseo, Cesare Gridelli, Stefano Cascinu, et al.
Cancer Immunology, Immunotherapy : CII|September 26, 2009
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancerRodolfo Passalacqua, Carlo Buzio, Sebastiano Buti, et al.
Oncology|February 5, 2003
Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?Tommaso de Pas, Paolo G Casali, Salvatore Toma, et al.
Tumori|August 19, 2004
45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003Raffaella Giavazzi, Massimo Aglietta, Annalisa Astolfi, et al.
Clinical Colorectal Cancer|April 12, 2015
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II StudyNicola Personeni, Lorenza Rimassa, Claudio Verusio, et al.
The Lancet. Oncology|September 4, 2009
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind studyGiancarlo Agnelli, Gualberto Gussoni, Carlo Bianchini, et al.
European Urology|September 12, 2012
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY)Sergio Bracarda, Camillo Porta, Corrado Boni, et al.
The Lancet. Oncology|December 14, 2007
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trialStefano Cascinu, Rossana Berardi, Roberto Labianca, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 9, 2003
Pain and its treatment in hospitalized patients with metastatic cancerStefano Cascinu, Paolo Giordani, Romina Agostinelli, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 22, 2014
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinomaValentina Vaira, Massimo Roncalli, Carlo Carnaghi, et al.
Pageof 18